SPOTLIGHT: New CEO at Bridge

There's a new slate of executives running Bridge Pharmaceuticals, which has been touting its facilities in China for preclinical contract research services. D. Thomas Oakley, a Covance vet, is the new CEO, Patrik Jeanmonod has been promoted to CFO and Dr. Ronald J. Ma is the new chief scientific officer. No word on the fate of their predecessors, the CEO abruptly left the scene months ago, or what triggered the change up. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.